Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon
- 10 July 1993
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 342 (8863), 80-83
- https://doi.org/10.1016/0140-6736(93)91286-u
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failureThe American Journal of Cardiology, 1991
- Digital Cutaneous Vascular Responses to Histamine and Neuropeptides in Raynaud's PhenomenonJournal of Investigative Dermatology, 1991
- Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failureJournal of the American College of Cardiology, 1991
- Effect of calcitonin-gene-related peptide on postoperative neurological deficits after subarachnoid haemorrhageThe Lancet, 1990
- Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failureCardiovascular Research, 1990
- Alternative production of calcitonin and CGRP mRNA is regulated at the calcitonin-specific splice acceptorNature, 1989
- Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.BMJ, 1989
- Substance P regulates the vasodilator activity of calcitonin gene-related peptideNature, 1988
- The treatment of Raynaud's phenomenonBritish Journal of Dermatology, 1986
- RAYNAUDʼS DISEASEThe American Journal of the Medical Sciences, 1932